CTX310

· CRISPR Therapeutics AG

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CTX310, covering 2026-03-24 to 2026-03-24. Get the full timeline:

Most recent: Clinical Trial Update: A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias [Phase 1]